GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Piotroski F-Score

Adaptive Biotechnologies (Adaptive Biotechnologies) Piotroski F-Score

: 1 (As of Today)
View and export this data going back to 2019. Start your Free Trial

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Adaptive Biotechnologies has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Adaptive Biotechnologies's Piotroski F-Score or its related term are showing as below:

ADPT' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 1

During the past 7 years, the highest Piotroski F-Score of Adaptive Biotechnologies was 4. The lowest was 1. And the median was 3.


Adaptive Biotechnologies Piotroski F-Score Historical Data

The historical data trend for Adaptive Biotechnologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only 4.00 2.00 3.00 4.00 1.00

Adaptive Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 3.00 3.00 1.00

Competitive Comparison

For the Biotechnology subindustry, Adaptive Biotechnologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -57.7 + -47.81 + -50.3 + -69.441 = $-225.3 Mil.
Cash Flow from Operations was -59.152 + -23.556 + -46.684 + -26.932 = $-156.3 Mil.
Revenue was 37.647 + 48.926 + 37.919 + 45.784 = $170.3 Mil.
Gross Profit was 18.966 + 31.016 + 18.573 + 26.168 = $94.7 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(856.617 + 791.463 + 764.54 + 717.682 + 661.134) / 5 = $758.2872 Mil.
Total Assets at the begining of this year (Dec22) was $856.6 Mil.
Long-Term Debt & Capital Lease Obligation was $89.4 Mil.
Total Current Assets was $410.2 Mil.
Total Current Liabilities was $88.0 Mil.
Net Income was -62.796 + -52.046 + -45.281 + -40.128 = $-200.3 Mil.

Revenue was 38.62 + 43.66 + 47.83 + 55.198 = $185.3 Mil.
Gross Profit was 25.428 + 30.439 + 32.923 + 38.609 = $127.4 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(923.344 + 858.193 + 806.633 + 884.208 + 856.617) / 5 = $865.799 Mil.
Total Assets at the begining of last year (Dec21) was $923.3 Mil.
Long-Term Debt & Capital Lease Obligation was $98.8 Mil.
Total Current Assets was $562.1 Mil.
Total Current Liabilities was $109.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Adaptive Biotechnologies's current Net Income (TTM) was -225.3. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Adaptive Biotechnologies's current Cash Flow from Operations (TTM) was -156.3. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-225.251/856.617
=-0.26295416

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-200.251/923.344
=-0.21687583

Adaptive Biotechnologies's return on assets of this year was -0.26295416. Adaptive Biotechnologies's return on assets of last year was -0.21687583. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Adaptive Biotechnologies's current Net Income (TTM) was -225.3. Adaptive Biotechnologies's current Cash Flow from Operations (TTM) was -156.3. ==> -156.3 > -225.3 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=89.388/758.2872
=0.11788146

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=98.772/865.799
=0.11408191

Adaptive Biotechnologies's gearing of this year was 0.11788146. Adaptive Biotechnologies's gearing of last year was 0.11408191. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=410.188/88.015
=4.66043288

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=562.146/109.788
=5.12028637

Adaptive Biotechnologies's current ratio of this year was 4.66043288. Adaptive Biotechnologies's current ratio of last year was 5.12028637. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Adaptive Biotechnologies's number of shares in issue this year was 144.906. Adaptive Biotechnologies's number of shares in issue last year was 143.061. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=94.723/170.276
=0.55629096

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=127.399/185.308
=0.68749865

Adaptive Biotechnologies's gross margin of this year was 0.55629096. Adaptive Biotechnologies's gross margin of last year was 0.68749865. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=170.276/856.617
=0.19877728

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=185.308/923.344
=0.20069227

Adaptive Biotechnologies's asset turnover of this year was 0.19877728. Adaptive Biotechnologies's asset turnover of last year was 0.20069227. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Adaptive Biotechnologies has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Adaptive Biotechnologies  (NAS:ADPT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Adaptive Biotechnologies Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").
Executives
Kyle Piskel officer: Principal Accounting Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood officer: Chief Commercial Officer, MRD C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson officer: Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams officer: Chief Operating Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor officer: SVP and General Counsel C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg director C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy director 5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno officer: Chief Commercial Ofc Imm Med C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins officer: Chief Scientific Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo officer: Chief People Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins director, officer: CEO and Chairman C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102

Adaptive Biotechnologies (Adaptive Biotechnologies) Headlines

From GuruFocus